Biologics: Targets & Therapy (May 2019)
Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
Abstract
LM Smirnova, E Yu Vertieva, O Yu Olisova, EM AnpilogovaDepartment of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russian FederationBackground: Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly affecting the distal phalanges of the fingers and toes. The disease manifests by pustular rash with marked infiltration, fissures, and often results into severe dystrophy of nail plates. ACH is refractory to most of psoriasis standard of care (SOC) therapies.Objective: The objective of this study is to assess the prospects of secukinumab therapy of ACH based on current clinical observation.Methods: We observed a female patient with ACH. Number of SOC treatments were applied in that case including local PUVA therapy, systemic retinoids, methotrexate, and biologic agents.Result: Secukinumab, a IL-17 inhibitor, demonstrated pronounced clinical effect in the case of ACH refractory to other SOC therapies.Conclusion: IL-17 inhibition provided by secukinumab was linked to clinically meaningful improvement in the heavily pretreated ACH. Further exploration and clinical studies may be important to provide more data on secukinumab effects in ACH.Keywords: acrodermatitis continua of Hallopeau, secukinumab, apremilast, anti IL-17A therapy, phosphodiesterase-4
